Although these products have been used for over two decades by patients and caregivers with great success, drug developers still seek to improve the patient experience
The active ingredients semaglutide and tirzepatide have been studied extensively in their branded forms but the compounded versions dispensed through partner pharmacies have not undergone FDA premarket review as finished products
Employer Benefits: Data on employer-provided coverage for GLP-1 agonists came from the KFF 2025 Employer Health Benefits Survey
Healthcare providers are incorporating these therapies into integrated care pathways for patients with multiple metabolic risk factors
This can get more people to their goals with fewer side effects
8.2 Cost-effectiveness and health economic implications The elevated cost of acquisition of GLP-1 receptor agonists convey major challenges for healthcare systems, with yearly treatment expenses between $10,000 and $15,000 USD, markedly surpassing those of conventional diabetic drugs (Kong et al
